Gilead Sciences announced that it's evaluating other ways it can use remdesivir for COVID-19 at an earlier stage of the disease, particularly through alternate formulations, such as one that's inhalable and a subcutaneous injection formulation.
Gilead plans easier-to-use remdesivir for COVID-19
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.